Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

Blood

Volumn 113, Issue 26, 2009, Pages 3572-3575

  Nair, Bijay ^a   Shaughnessy Jr , John D ^a   Zhou, Yiming ^a   Astrid Cartron, Marie ^a   Qu, Pingping ^b   Van Rhee, Frits ^a   Anaissie, Elias ^a   Alsayed, Yazan ^a   Waheed, Sarah ^a   Hollmig, Klaus ^a   Szymonifka, Jackie ^b   Petty, Nathan ^a   Hoering, Antje ^b   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; PROTEIN P53; THALIDOMIDE; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CONTINUOUS INFUSION; GENE DELETION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; MULTIPLE CYCLE TREATMENT; MYELOMA; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; BIOSYNTHESIS; CANCER STEM CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; PATHOLOGY; POLYPLOIDY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SALVAGE THERAPY; STATISTICS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PLASMA CELLS; POLYPLOIDY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SALVAGE THERAPY;

EID: 70449496661     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-207803     Document Type: Article

References (13)

1. Shaughnessy J, Zhan F, Burington B, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007; 109:2276-2284. (Pubitemid 46425864)
2. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol. 2005;23: 6339-6344. (Pubitemid 46218844)
3. Zhan F, Barlogie B, Mulligan G, et al. High risk myeloma: a gene expression-based risk stratification model for newly diagnosed multiple myeloma treated with high dose therapy is predictive of outcome in relapsed disease treated with single agent bortezomib and high-dose dexamethasone. Blood. 2008;111:968-969.
4. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030. (Pubitemid 43357806)
5. Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112:3115-3121.
6. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006; 108:2020-2028.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
8. Wilcoxon F. Individual comparisons by ranking methods. Biometrics. 1945;1:80-83.
9. O'Quigly J, Xu R. Explained variation in proportional hazards regression. In: Crowley J, Ankerst DP, eds. Handbook of Statistics in Clinical Oncology. 2nd Ed. Boca Raton, FL: Chapman & Hall/ CRC Press; 2006:347-364.
10. Cox DR. Regression models and life-tables. J R Stat Soc [B]. 1972;34:187-202.
11. Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008;112:4235-4246.
12. Fisher RI, DeVita VT, Hubbard SP, Simon R, Young RC. Importance of response duration for post-relapse survival: Hodgkin's disease with MOPP re-induction after first relapse. Ann Intern Med. 1979;90:761-763.
13. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109:3177-3188. (Pubitemid 46572502)